AIM Concept Integration
Histamine and Serotonin Pharmacology, Antidotes and General Management of Poisoning
3rd Year MBBS • Infection and Inflammation
Connect the major pharmacological and toxicological concepts for rapid revision.
1. THE TOPIC IN ONE CONNECTED FLOW
This topic links chemical mediators with drugs that modify their effects and then applies the same receptor-and-mechanism approach to poisoning. Histamine and serotonin produce effects through specific receptors, while antihistamines, serotonin agonists or antagonists, and antidotes act at selected points to reduce symptoms or toxicity.
Mediator or Toxic Exposure
Histamine, serotonin or poison enters its relevant pathway
→
Specific Target
H1, 5-HT receptor, enzyme or toxic binding site
→
Functional Change
Vascular, neural, gastrointestinal or systemic effect develops
→
Clinical Manifestation
Allergy, vomiting, migraine-related symptoms or toxicity
→
Targeted Intervention
Block, stimulate, bind or reverse the responsible pathway
→
Clinical Outcome
Reduced symptoms or toxicity with supportive monitoring
Histamine branch
Histamine → H1 receptor → vascular permeability + sensory stimulation → wheal, edema and itching → H1 antagonist → symptom reduction
Serotonin branch
Serotonin → selected 5-HT receptor → organ-specific effect → receptor-selective agonist or antagonist → therapeutic effect
Poisoning branch
Toxin exposure → physiological dysfunction → clinical toxicity → ABC stabilization + exposure control + supportive care ± antidote → reassessment
2. KEY CLINICAL CONNECTIONS
H1 Antihistamines
First generation → enters CNS → sedation + antimuscarinic effects
→
second generation → limited CNS entry → preferred when daytime alertness is important
Chemotherapy-Induced Vomiting
Chemotherapy → serotonin release from enterochromaffin cells → 5-HT3 activation on vagal afferents
→
ondansetron blocks 5-HT3 → emetic signaling decreases
Poisoning Management
Toxic exposure → possible airway, breathing or circulatory compromise
→
stabilize first → then identify exposure, limit absorption, support functions and use antidote when indicated
3. AIM HIGH-YIELD INTEGRATION REVIEW
⭐ First-generation H1 antagonists → greater CNS penetration → more sedation and more antimuscarinic adverse effects.
Second-generation H1 antagonists → limited CNS penetration → effective peripheral antiallergic action with less sedation.
H1 blockade → reduced vascular permeability and sensory nerve stimulation → less wheal formation, edema and pruritus.
⭐ Serotonin effects vary because different tissues express different 5-HT receptor subtypes; 5-HT3 is distinctive because it is a ligand-gated ion channel.
Sumatriptan → 5-HT1B/1D agonism → therapeutic action in migraine; cyproheptadine → 5-HT2 blockade with antihistaminic activity.
⭐ Chemotherapy → gastrointestinal serotonin release → vagal 5-HT3 activation → vomiting; ondansetron interrupts this pathway by blocking 5-HT3 receptors.
Antidotes may work by physical adsorption, chemical binding or chelation, receptor antagonism, physiological opposition, or biochemical restoration.
⭐ In poisoning, airway, breathing and circulation come before specific antidote therapy → supportive care continues while the toxin is identified, removed or metabolized.
AIM Exam Trap: An antidote does not replace resuscitation. Even when a specific antidote is available, stabilization, supportive care and continued reassessment remain essential.